NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy

SIMPLE SUMMARY: eIF4A-targeted translational inhibitors, such as silvestrol and its analogues, have emerged as strong anticancer therapies. Here, we tested the efficacy of eIF4A inhibition across a large and diverse panel of cancer cell lines and found B cell lymphomas to be the most sensitive group...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanghvi, Viraj R., Mohan, Prathibha, Singh, Kamini, Cao, Linlin, Berishaj, Marjan, Wolfe, Andrew L., Schatz, Jonathan H., Lailler, Nathalie, de Stanchina, Elisa, Viale, Agnes, Wendel, Hans-Guido
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7915661/
https://www.ncbi.nlm.nih.gov/pubmed/33562682
http://dx.doi.org/10.3390/cancers13040639

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7915661/
https://www.ncbi.nlm.nih.gov/pubmed/33562682
http://dx.doi.org/10.3390/cancers13040639

Ejemplares similares